Active Filter(s):
Details:
VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJI).
Lead Product(s): Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
The proceeds will support NDA submission and preparation for commercial launch of company's VT-X7, a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin hydrochloride and tobramycin, for periprosthetic joint infection.
Lead Product(s): Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Asteroid Partners
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 21, 2023
Details:
VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJI).
Lead Product(s): Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area: Musculoskeletal Product Name: VT-X7
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023